title: Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats.
abstract: Previous studies in our laboratory have shown that the semisynthetic bile acid derivative, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate (MKC), has hypoglycemic activity. The aim of this study was to investigate the relationship between the pharmacokinetics and hypoglycemic activity of MKC in healthy and diabetic rats. Groups of healthy and alloxan-induced diabetic rats were dosed intravenously (i.v.) and orally with MKC (4 mg/kg). Blood samples were taken before administration of the dose and at 20, 40, 60, 80, 120, 150, 180, 210 and 240 minutes post-dose. MKC serum concentration was measured by HPLC, and pharmacokinetic parameters determined using the WinNonlin program. The absolute bioavailability of MKC was found to be low in healthy and diabetic rats (29 and 23% respectively) and was not significantly different between the two groups. Mean residence time (MRT), volume of distribution (Vd) and half-life (t1/2) of MKC after oral administration were significantly lower in diabetic than in healthy rats (21, 31 and 29% respectively). After the i.v. dose, the change in blood glucose concentration was not significant in either healthy or diabetic rats. After the oral dose, the decrease in blood glucose concentration was significant, reaching a maximum decrease from baseline of 24% in healthy rats and 15% in diabetic rats. The results suggest that a first-pass effect is crucial for the hypoglycemic activity of MKC, indicating that a metabolite of MKC and/or interference with metabolism and glucose transport is responsible.
authors.affiliation: School of Pharmacy, University of Otago, Dunedin, New Zealand.
authors.forename: M
authors.initials: M
authors.lastname: Mikov
authors.forename: N S
authors.initials: NS
authors.lastname: Boni
authors.forename: H
authors.initials: H
authors.lastname: Al-Salami
authors.forename: K
authors.initials: K
authors.lastname: Kuhajda
authors.forename: S
authors.initials: S
authors.lastname: Kevresan
authors.forename: S
authors.initials: S
authors.lastname: Golocorbin-Kon
authors.forename: J P
authors.initials: JP
authors.lastname: Fawcett
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001711:Biotransformation; D001786:Blood Glucose / Q000187:drug effects*; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D007276:Injections, Intraventricular; D008954:Models, Biological; D051381:Rats; D013997:Time Factors
chemical_list: C520227:3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D002635:Chenodeoxycholic Acid